Market Overview

Clovis Shares Reiterated As A Sell Following 10% Rally

Share:
Related CLVS
What To Expect From Clovis Oncology Following Rubraca Approval
12 Biggest Mid-Day Losers For Friday
The Vetr community has downgraded $CLVS to 3-Stars (Vetr)

AstraZeneca plc (ADR) (NYSE: AZN) on Tuesday presented positive Lynparza results in ovarian cancer maintenance. This raises competitive risks for Clovis Oncology Inc’s (NASDAQ: CLVS) Rubraca, which is currently in the phase III ARIEL3 maintenance study, Chardan Capital Markets’ Madhu Kumar said in a report.

Madhu reiterated a Sell rating for Clovis, with a price target of $36.

Increased Competition

Clovis is expected to present top-line results from Rubraca’s phase III ARIEL3 maintenance study in mid-2017.

“While we understand that success for a second PARPi in the setting of ovarian cancer maintenance therapy arguably further de-risks PARPi as a class in the indication, this de-risking needs to be balanced by the competitive pressures generated by multiple effective PARPis in the ovarian cancer space,” Madhu wrote.

Related Link: Wall Street's M&A Chatter From March 10-12

Moreover, positive results for competitors in the second-line maintenance setting exerts pressure on Rubraca's approved indication of third line or later therapy. The analyst added that the positive SOLO-2 result presented by AstraZeneca “raises the possible risk” of ARIEL3 failing in an absolute or relative sense.

Although Rubraca is being tested for another major indication, that of metastatic castrate-resistant prostate cancer, there are several PARPi competitors in development in combination with AR [androgen receptor] inhibitors, Madhu noted.

Latest Ratings for CLVS

DateFirmActionFromTo
Jul 2017Gabelli & Co.Initiates Coverage OnBuy
Jun 2017OppenheimerInitiates Coverage OnMarket Perform
Jun 2017Janney CapitalUpgradesNeutralBuy

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Chardan Capital Markets Madhu Kumar RubracaAnalyst Color Short Ideas Reiteration Analyst Ratings Trading Ideas

 

Related Articles (AZN + CLVS)

View Comments and Join the Discussion!